Posoleucel (ALVR105) for Epstein-Barr Virus (EBV) Infection

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Loyola University, Maywood, ILEpstein-Barr Virus (EBV) Infection+5 MorePosoleucel (ALVR105) - Biological
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test an allogeneic, multi-virus specific T cell therapy for six viral pathogens.

Eligible Conditions
  • Epstein-Barr Virus (EBV) Infection
  • Adenovirus Infections
  • BK Virus Infection
  • Cytomegalovirus (CMV)
  • Human Herpes Virus 6 (HHV-6) Infection
  • Progressive Multifocal Leukoencephalopathy (PML)

Treatment Effectiveness

Study Objectives

0 Primary · 5 Secondary · Reporting Duration: Through Week 14 and 26

Week 14
Mean area under the curve (AUC) viral load
Number of clinically significant infections or episodes of end-organ disease due to each virus
Through Week 26
Incidence of Adverse Events
Number of clinically significant infections or episodes of end-organ disease
Overall and Non-Relapse Mortality

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Posoleucel (ALVR105)
1 of 2
Placebo
1 of 2

Active Control

Non-Treatment Group

302 Total Participants · 2 Treatment Groups

Primary Treatment: Posoleucel (ALVR105) · Has Placebo Group · Phase 2 & 3

Posoleucel (ALVR105)
Biological
ActiveComparator Group · 1 Intervention: Posoleucel (ALVR105) · Intervention Types: Biological
Placebo
Biological
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through week 14 and 26

Who is running the clinical trial?

AlloVirLead Sponsor
11 Previous Clinical Trials
494 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You received a stem cell transplant from a donor who is not related to you.
You cannot participate if your stem cells will be obtained from umbilical cord blood.
The donor for the transplant is only a half-match to you.

Who else is applying?

What state do they live in?
Florida100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%
Why did patients apply to this trial?
  • "I have been dealing with CFS for 3 years now. Age 80. Never been a drinker or smoker. CFS seems to be getting worse. Huge CRP labs. Tested positive for EBV in 3 different simultaneous tests. Chemical engineer. Widowed."
How many prior treatments have patients received?
0100.0%

Frequently Asked Questions

Could you estimate how many hospitals are running this trial?

"To make enrolling easier for patients, this trial is being run out of 50 locations. 3 of these sites are in Richmond, Nashville and Toronto with the other 47 located elsewhere." - Anonymous Online Contributor

Unverified Answer

Are people still being sought out for this research project?

"This study, which can be found on clinicaltrials.gov, is looking for participants. The trial was first posted on March 21st, 2022 and was last edited on November 8th, 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.